Recently, selective improvement of the levels and function of Tregs has been demonstrated as a result of the low-dose IL-2 immunotherapy in the experimental model of autoimmune disorders [18–23] as well as in the phase I/II clinical trial in patients with type 1 diabetes [24]. The gene discussed is IL2; the disease is autoimmune disease.